PreMD to be Delisted on AMEX

    TORONTO, Aug. 21 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex:   PME) today announced that it has received notice from the American
Stock Exchange LLC (the "AMEX" or "Exchange") that it intends to suspend
trading in PreMD's stock on the AMEX effective August 28, 2008 and to initiate
delisting proceedings.
    PreMD originally received notification of the Exchange's intention to
delist on May 28, 2008. The Company appealed this decision and a hearing was
held with the Listing Qualifications Panel on August 12, 2008. The panel also
considered the Company's recent press release on August 18, 2008 announcing
that the U.S. Food and Drug Administration (the "FDA") had upheld its previous
decision regarding the Non-Substantially Equivalent letter with respect to
PreMD's skin cholesterol test. Based on the written submissions, oral
presentations and the recent announcement, the panel unanimously affirmed the
determination to delist the common stock of the Company.
    The AMEX stated that the basis for its determination to delist the
Company's common stock was based upon the Company being non-compliant with
Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the AMEX Company Guide,
all of which relate to the Company's insufficient stockholder's equity as
previously reported in the Company's filings with the SEC. PreMD continues to
trade on the Toronto Stock Exchange (the "TSX") under the symbol PMD.

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive skin
cholesterol tests. PreMD's other skin cholesterol products include PREVU(*) LT,
a skin cholesterol test designed for use in the life insurance industry. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For more information about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain continued
listing standards of the American Stock Exchange, successful development or
marketing of the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance on
third-party manufacturers, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the protection
offered by the Company's patents and patent applications may be challenged,
invalidated or circumvented by our competitors and there can be no guarantee
of our ability to obtain or maintain patent protection for our products or
product candidates.
    Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.


    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Ron Hosking, Vice President Finance & CFO, Tel:
(416) 222-3449, Email:; Brent Norton, President and CEO,
Tel: (416) 222-3449, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890